Jiangsu COAST PHARMACEUTICAL CO., LTD

Primary objective: To investigate the pharmacokinetic behavior of the test formulation (T, strength: 2 mg, Jiangsu Coast Pharmaceutical Co., Ltd.) and the reference formulation (R, trade name: URECE®, strength: 2 mg, Fuji Pharmaceutical Co., Ltd.) after a single oral dose in healthy study participants under fasting and postprandial conditions, to evaluate the bioequivalence trend of the two formulations, and to provide a basis for formal trials. Secondary objective: To evaluate the safety of the test formulation docenolactone tablets and the reference formulation URECE® in healthy study participants.

The pharmacokinetic behavior of the test formulation of posaconazole enteric-coated tablets (specification: 100 mg, Yangtze River Pharmaceutical Group Co., Ltd.) and the reference formulation (NocoFy®, specification: 100 mg, licensee: Merck Sharp & Dohme Ltd; manufacturer: N.V.Organon) in healthy subjects after a single oral administration in the fasting and postprandial state was studied to evaluate the bioequivalence of the two formulations. The safety of the test formulation and the reference formulation (trade name: NocoFy®) in healthy subjects was evaluated.

The pharmacokinetic behavior of the single-use crisaborole ointment test formulation (Specification: 20 mg crisaborole (2%) per gram of this product, provided by Jiangsu Coast Pharmaceutical Co., Ltd.) and the reference formulation (trade name: Sutanming®/Staquis®, Specification: 20 mg crisaborole (2%) per gram of this product, Pharmacia and Upjohn Company LLC) in healthy subjects was studied to evaluate the bioequivalence of the two formulations. The safety of the test formulation and the reference formulation (trade name: Sutanming®/Staquis®) in healthy subjects was observed.